Drug Profile
Research programme: chemokine receptor modulators - ChemDiv/Ogeda
Alternative Names: G protein-coupled receptor modulators - ChemDiv/Ogeda; GPCR modulators - ChemDiv/OgedaLatest Information Update: 18 May 2017
Price :
$50
*
At a glance
- Originator ChemDiv; Euroscreen
- Developer ChemDiv
- Class
- Mechanism of Action G protein-coupled receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer; Immunological disorders; Inflammation
Most Recent Events
- 16 May 2017 Ogeda has been acquired by and became a wholly-owned subsidiary of Astellas Pharma
- 19 Oct 2016 Euroscreen is now called Ogeda
- 26 Mar 2009 Discontinued - Preclinical for Cancer in Belgium (unspecified route)